Literature DB >> 22802077

CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.

William C Reinhold1, Margot Sunshine, Hongfang Liu, Sudhir Varma, Kurt W Kohn, Joel Morris, James Doroshow, Yves Pommier.   

Abstract

High-throughput and high-content databases are increasingly important resources in molecular medicine, systems biology, and pharmacology. However, the information usually resides in unwieldy databases, limiting ready data analysis and integration. One resource that offers substantial potential for improvement in this regard is the NCI-60 cell line database compiled by the U.S. National Cancer Institute, which has been extensively characterized across numerous genomic and pharmacologic response platforms. In this report, we introduce a CellMiner (http://discover.nci.nih.gov/cellminer/) web application designed to improve the use of this extensive database. CellMiner tools allowed rapid data retrieval of transcripts for 22,379 genes and 360 microRNAs along with activity reports for 20,503 chemical compounds including 102 drugs approved by the U.S. Food and Drug Administration. Converting these differential levels into quantitative patterns across the NCI-60 clarified data organization and cross-comparisons using a novel pattern match tool. Data queries for potential relationships among parameters can be conducted in an iterative manner specific to user interests and expertise. Examples of the in silico discovery process afforded by CellMiner were provided for multidrug resistance analyses and doxorubicin activity; identification of colon-specific genes, microRNAs, and drugs; microRNAs related to the miR-17-92 cluster; and drug identification patterns matched to erlotinib, gefitinib, afatinib, and lapatinib. CellMiner greatly broadens applications of the extensive NCI-60 database for discovery by creating web-based processes that are rapid, flexible, and readily applied by users without bioinformatics expertise.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22802077      PMCID: PMC3399763          DOI: 10.1158/0008-5472.CAN-12-1370

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities.

Authors:  Hongfang Liu; Petula D'Andrade; Stephanie Fulmer-Smentek; Philip Lorenzi; Kurt W Kohn; John N Weinstein; Yves Pommier; William C Reinhold
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

2.  Tumorigenicity of the miR-17-92 cluster distilled.

Authors:  Gijs van Haaften; Reuven Agami
Journal:  Genes Dev       Date:  2010-01-01       Impact factor: 11.361

3.  Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.

Authors:  Susan L Holbeck; Jerry M Collins; James H Doroshow
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

4.  Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron.

Authors:  William C Reinhold; Jean-Louis Mergny; Hongfang Liu; Michael Ryan; Thomas D Pfister; Robert Kinders; Ralph Parchment; James Doroshow; John N Weinstein; Yves Pommier
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

5.  ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1.

Authors:  E Sánchez-Tilló; A Lázaro; R Torrent; M Cuatrecasas; E C Vaquero; A Castells; P Engel; A Postigo
Journal:  Oncogene       Date:  2010-04-26       Impact factor: 9.867

6.  Multifactorial regulation of E-cadherin expression: an integrative study.

Authors:  William C Reinhold; Mark A Reimers; Philip Lorenzi; Jennifer Ho; Uma T Shankavaram; Micah S Ziegler; Kimberly J Bussey; Satoshi Nishizuka; Ogechi Ikediobi; Yves G Pommier; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

7.  E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.

Authors:  Volodymyr P Tryndyak; Frederick A Beland; Igor P Pogribny
Journal:  Int J Cancer       Date:  2010-06-01       Impact factor: 7.396

8.  MicroRNA expression profiles for the NCI-60 cancer cell panel.

Authors:  Paul E Blower; Joseph S Verducci; Shili Lin; Jin Zhou; Ji-Hyun Chung; Zunyan Dai; Chang-Gong Liu; William Reinhold; Philip L Lorenzi; Eric P Kaldjian; Carlo M Croce; John N Weinstein; Wolfgang Sadee
Journal:  Mol Cancer Ther       Date:  2007-05-04       Impact factor: 6.261

9.  DNA fingerprinting of the NCI-60 cell line panel.

Authors:  Philip L Lorenzi; William C Reinhold; Sudhir Varma; Amy A Hutchinson; Yves Pommier; Stephen J Chanock; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

10.  Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.

Authors:  Thomas D Pfister; William C Reinhold; Keli Agama; Shalu Gupta; Sonny A Khin; Robert J Kinders; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2009-07-07       Impact factor: 6.261

View more
  291 in total

1.  A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.

Authors:  Peter M Bruno; Yunpeng Liu; Ga Young Park; Junko Murai; Catherine E Koch; Timothy J Eisen; Justin R Pritchard; Yves Pommier; Stephen J Lippard; Michael T Hemann
Journal:  Nat Med       Date:  2017-02-27       Impact factor: 53.440

2.  Comprehensive characterization of the Published Kinase Inhibitor Set.

Authors:  Jonathan M Elkins; Vita Fedele; Marta Szklarz; Kamal R Abdul Azeez; Eidarus Salah; Jowita Mikolajczyk; Sergei Romanov; Nikolai Sepetov; Xi-Ping Huang; Bryan L Roth; Ayman Al Haj Zen; Denis Fourches; Eugene Muratov; Alex Tropsha; Joel Morris; Beverly A Teicher; Mark Kunkel; Eric Polley; Karen E Lackey; Francis L Atkinson; John P Overington; Paul Bamborough; Susanne Müller; Daniel J Price; Timothy M Willson; David H Drewry; Stefan Knapp; William J Zuercher
Journal:  Nat Biotechnol       Date:  2015-10-26       Impact factor: 54.908

3.  rcellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in R.

Authors:  Augustin Luna; Vinodh N Rajapakse; Fabricio G Sousa; Jianjiong Gao; Nikolaus Schultz; Sudhir Varma; William Reinhold; Chris Sander; Yves Pommier
Journal:  Bioinformatics       Date:  2015-12-03       Impact factor: 6.937

4.  Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.

Authors:  Priya Samuel; Ryan Charles Pink; Daniel Paul Caley; James Michael Stevenson Currie; Susan Ann Brooks; David Raul Francisco Carter
Journal:  Tumour Biol       Date:  2015-09-19

5.  YY1 regulated transcription-based stratification of gastric tumors and identification of potential therapeutic candidates.

Authors:  Divya Bhaskar Rao; Ponmathi Panneerpandian; Karthik Balakrishnan; Kumaresan Ganesan
Journal:  J Cell Commun Signal       Date:  2021-02-23       Impact factor: 5.782

6.  Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).

Authors:  Martin Conda-Sheridan; P V Narasimha Reddy; Andrew Morrell; Brooklyn T Cobb; Christophe Marchand; Keli Agama; Adel Chergui; Amélie Renaud; Andrew G Stephen; Lakshman K Bindu; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2012-12-21       Impact factor: 7.446

Review 7.  Drugging topoisomerases: lessons and challenges.

Authors:  Yves Pommier
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

8.  Transcriptional profiling reveals elevated Sox2 in DNA polymerase ß null mouse embryonic fibroblasts.

Authors:  Jianfeng Li; Soumya Luthra; Xiao-Hong Wang; Uma R Chandran; Robert W Sobol
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

9.  Chromatin Regulators as a Guide for Cancer Treatment Choice.

Authors:  Zachary A Gurard-Levin; Laurence O W Wilson; Vera Pancaldi; Sophie Postel-Vinay; Fabricio G Sousa; Cecile Reyes; Elisabetta Marangoni; David Gentien; Alfonso Valencia; Yves Pommier; Paul Cottu; Geneviève Almouzni
Journal:  Mol Cancer Ther       Date:  2016-05-16       Impact factor: 6.261

10.  Genome-Wide Analysis of the FOXA1 Transcriptional Network Identifies Novel Protein-Coding and Long Noncoding RNA Targets in Colorectal Cancer Cells.

Authors:  Sarah B Lazar; Lorinc Pongor; Xiao Ling Li; Ioannis Grammatikakis; Bruna R Muys; Emily A Dangelmaier; Christophe E Redon; Sang-Min Jang; Robert L Walker; Wei Tang; Stefan Ambs; Curtis C Harris; Paul S Meltzer; Mirit I Aladjem; Ashish Lal
Journal:  Mol Cell Biol       Date:  2020-10-13       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.